ACCDiS

Confusión respecto a Pembrolizumab (Keytruda), una droga que anuncia un esperado cambio sobre el tratamiento del cáncer.

[vc_row][vc_column width=»3/4″ css=».vc_custom_1523478190577{padding-right: 35px !important;}»][stm_post_info][vc_column_text]

A landmark cancer drug approved last year seemed to herald a long-anticipated change in the treatment of some tumours: with medicines selected on the basis of molecular markers, rather than the tissue in which the cancer first took root.

Noticia completa

[/vc_column_text][/vc_column][vc_column width=»1/4″][vc_widget_sidebar sidebar_id=»default»][/vc_column][/vc_row]